Refine
Has Fulltext
- yes (4)
Is part of the Bibliography
- yes (4)
Document Type
- Journal article (3)
- Doctoral Thesis (1)
Keywords
- ADHD (1)
- Angst (1)
- BDNF (1)
- DM2 (1)
- NIRS (1)
- PARK2 (1)
- TMS (1)
- VFT (1)
- brain derived neurotrophic factor (1)
- disease modelling (1)
Institute
Angsterkrankungen stellen einen großen Anteil an psychischen Erkrankungen dar und gehen zum Teil mit großem Leidensdruck einher. Da die leitliniengerechte Therapie mit hohen Rückfallraten und ca. 25% Nonrespondern einhergeht, stellt sich die Frage nach alternativen Behandlungsmethoden. Transkranielle Magnetstimulation findet als nichtinvasive Behanslungsmethode zunehmend Anwendung bei neurologischen und psychiatrischen Erkrankungen.
In der vorliegenden randomisierten, kontrollierten Studie wurde die Wirkung der TMS auf den frontotemporalen (FTC) und dorsolateralen präfrontalen Cortex (dlPFC) untersucht. Dazu wurden 42 gesunde Probanden zwischen 18 und 59 Jahren zur Hälfte TMS-stimuliert, die andere Hälfte wurde scheinstimuliert. Vor und nach Stimulation bzw. Placebostimulation wurde die Aktivität von FTC und dlPFC mit Nah-Infrarotspektroskopie (NIRS) während der Durchführung des Verbal Fluency Tasks (VFT) gemessen.
In dieser Studie konnte keine Veränderung der hämodynamischen Gehirnaktivität durch TMS nachgewiesen werden, jedoch äußerten die Probanden der Stimulationsgruppe im Gegensatz zu den Probanden der Placebogruppe, Nebenwirkungen wie Schmerzen oder Muskelzucken verspürt zu haben.
Die während des VFT laufende NIRS zeigte eine signifikant höhere Durchblutung und damit Aktivierung des linken FTC im Seitenvergleich und eine signifikant höhere Aktivierung während der semantischen als bei der phonemischen VFT-Bedingung, analog zu früheren, vergleichbaren Untersuchungen.
Die Frage, ob sich TMS als mögliche Behandlungsmethode bei Angsterkrankungen eignet, lässt sich anhand der hier vorliegenden Studie nicht abschließend beantworten.
The main goal of the present study was the identification of cellular phenotypes in attention-deficit-/hyperactivity disorder (ADHD) patient-derived cellular models from carriers of rare copy number variants (CNVs) in the PARK2 locus that have been previously associated with ADHD. Human-derived fibroblasts (HDF) were cultured and human-induced pluripotent stem cells (hiPSC) were reprogrammed and differentiated into dopaminergic neuronal cells (mDANs). A series of assays in baseline condition and in different stress paradigms (nutrient deprivation, carbonyl cyanide m-chlorophenyl hydrazine (CCCP)) focusing on mitochondrial function and energy metabolism (ATP production, basal oxygen consumption rates, reactive oxygen species (ROS) abundance) were performed and changes in mitochondrial network morphology evaluated. We found changes in PARK2 CNV deletion and duplication carriers with ADHD in PARK2 gene and protein expression, ATP production and basal oxygen consumption rates compared to healthy and ADHD wildtype control cell lines, partly differing between HDF and mDANs and to some extent enhanced in stress paradigms. The generation of ROS was not influenced by the genotype. Our preliminary work suggests an energy impairment in HDF and mDAN cells of PARK2 CNV deletion and duplication carriers with ADHD. The energy impairment could be associated with the role of PARK2 dysregulation in mitochondrial dynamics.
Background:
Memory reconsolidation is the direct effect of memory reactivation followed by stabilization of newly synthesized proteins. It has been well proven that neural encoding of both newly and reactivated memories requires synaptic plasticity. Brain derived neurotrophic factor (BDNF) has been extensively investigated regarding its role in the formation of synaptic plasticity and in the alteration of fear memories. However, its role in fear reconsolidation is still unclear; hence, the current study has been designed to investigate the role of the BDNF val66met polymorphism (rs6265) in fear memory reconsolidation in humans.
Methods:
An auditory fear-conditioning paradigm was conducted, which comprised of three stages (acquisition, reactivation, and spontaneous recovery). One day after fear acquisition, the experimental group underwent reactivation of fear memory followed by the extinction training (reminder group), whereas the control group (non-reminder group) underwent only extinction training. On day 3, both groups were subjected to spontaneous recovery of earlier learned fearful memories. The treat-elicited defensive response due to conditioned threat was measured by assessing the skin conductance response to the conditioned stimulus. All participants were genotyped for rs6265.
Results:
The results indicate a diminishing effect of reminder on the persistence of fear memory only in the Met-allele carriers, suggesting a moderating effect of the BDNF polymorphism in fear memory reconsolidation.
Conclusions:
Our findings suggest a new role for BDNF gene variation in fear memory reconsolidation in humans.
Autosomal dominant inherited Myotonic dystrophy type 1 and 2 (DM1 and DM2) are the most frequent muscle dystrophies in the European population and are caused by repeat expansion mutations. For Germany cumulative empiric evidence suggests an estimated prevalence of DM2 of roughly 9 in 100,000, therefore being as prevalent as DM1. In DM2, a (CCTG)n repeat tract located in the first intron of the CNBP gene is expanded. The CCTG repeat tract is part of a complex repeat structure comprising not only CCTG tetraplets but also repeated TG dinucleotides and TCTG tetraplet elements as well as NCTG interruptions. Here, we provide the distribution of normal sized alleles in the German population, which was found to be highly similar to the Slovak population. Sequencing of 34 unexpanded healthy range alleles in DM2 positive patients (heterozygous for a full expansion) revealed that the CCTG repeat tract is usually interrupted by at least three tetraplets which according to current opinion is supposed to render it stable against expansion. Interestingly, only the largest analyzed normal allele had 23 uninterrupted CCTGs and consequently could represent an instable early premutation allele. In our diagnostic history of DM2 cases, a total of 18 premutations were detected in 16 independent cases. Here, we describe two premutation families, one with an expansion from a premutation allele and the other with a contraction of a full expansion down to a premutation allele. Our diagnostic results support the general assumption that the premutation range of unstable CCTG stretches lies obviously between 25 and 75 CCTGs. However, the clinical significance of premutation alleles is still unclear. In the light of the two described families we suggest incomplete penetrance. Thus, as it was proposed for other repeat expansion diseases (e.g., Huntington's disease), a fluid transition of penetrance is more likely rather than a clear cut CCTG number threshold.